CN103330713A - Application of Aspeverin in preparation of medicine for treating tongue cancer - Google Patents
Application of Aspeverin in preparation of medicine for treating tongue cancer Download PDFInfo
- Publication number
- CN103330713A CN103330713A CN201310304500XA CN201310304500A CN103330713A CN 103330713 A CN103330713 A CN 103330713A CN 201310304500X A CN201310304500X A CN 201310304500XA CN 201310304500 A CN201310304500 A CN 201310304500A CN 103330713 A CN103330713 A CN 103330713A
- Authority
- CN
- China
- Prior art keywords
- aspeverin
- medicine
- tongue cancer
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Aspeverin in preparation of a medicine for treating tongue cancer, and belongs to the technical field of new applications of the medicine. According to the invention, evaluation of extracorporeal MTT antineoplastic activity shows that Aspeverin has an obvious inhibiting effect on growths of tongue cancer cell strain PTca8113 and T6, so that Aspeverin can be used for preparing the tongue cancer resistance medicine, and has good development and application prospects. The application of Aspeverin in preparation of the medicine for treating the tongue cancer is disclosed for the first time, and the inhibitory activity of Aspeverin on tongue cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compd A speverin, relate in particular to the application of Aspeverin in preparation treatment carcinoma of tongue medicine.
Background technology
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compd A speverin that the present invention relates to is one and delivered (Nai-Yun Ji in 2013, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.) noval chemical compound, this chemical compound has brand-new framework types, present purposes only relates to and suppresses to swim vegeto-animal growth (Nai-Yun Ji, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.), the purposes of the Aspeverin that the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first.
Summary of the invention
The objective of the invention is to provides the application of Aspeverin in the anti-carcinoma of tongue medicine of preparation according to not finding that it has the present situation of the report of anti-carcinoma of tongue activity in the existing Aspeverin research.
Described compd A speverin, structure is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation the growth of the people's carcinoma of tongue of Aspeverin cell strain PTca8113 and T6 also has significant inhibitory effect, and the IC50 value that suppresses this 2 strain cell growth is respectively 1.91 ± 0.28 μ M and 1.52 ± 0.28 μ M.Therefore, Aspeverin can have the excellent development application prospect for the preparation of anti-carcinoma of tongue medicine.
Belong to open first for the purposes of the Aspeverin that the present invention relates in preparation treatment carcinoma of tongue medicine, because framework types belongs to brand-new framework types, and it is unexpectedly strong for the carcinoma of tongue cell inhibiting activity, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for carcinoma of tongue simultaneously obviously has obvious improvement.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compd A speverin involved in the present invention is referring to document (Nai-Yun Ji, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd A speverin tablet involved in the present invention:
Get 5 and digest compound Aspeverin, add dextrin 195 grams, mixing, conventional tabletting are made 1000.
Embodiment 2: the preparation of compd A speverin capsule involved in the present invention:
Get 5 and digest compound Aspeverin, add starch 195 grams, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of the people's carcinoma of tongue of mtt assay assessing compound Aspeverin cell strain
1. method: the cell that is in the growth logarithmic (log) phase: people's carcinoma of tongue cell strain PTca8113 and T6(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Cell culture 24h inhales adherent back and goes original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Aspeverin of 0.01 μ M and 0.001 μ M.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4h, inhales along culture fluid top then and removes 100 μ L supernatants, adds 100 μ L DMSO, 10min is placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculate the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD drug treating/Δ OD blank * 100.
2. the growth of the people's carcinoma of tongue of result: Aspeverin cell strain P PTca8113 and T6 has significant inhibitory effect.The IC50 value that this chemical compound suppresses people carcinoma of tongue cell strain PTca8113 and T6 growth is respectively 1.91 ± 0.28 μ M and 1.52 ± 0.28 μ M.
Shown that by above-described embodiment the growth of the people's carcinoma of tongue of Aspeverin of the present invention cell strain PTca8113 and T6 has the good restraining effect.Prove that thus Aspeverin of the present invention has anti-carcinoma of tongue activity, can be for the preparation of anti-carcinoma of tongue medicine.
Claims (1)
1.Aspeverin the application in preparation treatment carcinoma of tongue medicine, described compd A speverin structure is shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310304500XA CN103330713A (en) | 2013-07-17 | 2013-07-17 | Application of Aspeverin in preparation of medicine for treating tongue cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310304500XA CN103330713A (en) | 2013-07-17 | 2013-07-17 | Application of Aspeverin in preparation of medicine for treating tongue cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103330713A true CN103330713A (en) | 2013-10-02 |
Family
ID=49238963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310304500XA Pending CN103330713A (en) | 2013-07-17 | 2013-07-17 | Application of Aspeverin in preparation of medicine for treating tongue cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103330713A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251609A (en) * | 2013-06-03 | 2013-08-21 | 南京正亮医药科技有限公司 | Application of Aspeverin in preparation of medicines for treating tongue cancer |
-
2013
- 2013-07-17 CN CN201310304500XA patent/CN103330713A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251609A (en) * | 2013-06-03 | 2013-08-21 | 南京正亮医药科技有限公司 | Application of Aspeverin in preparation of medicines for treating tongue cancer |
Non-Patent Citations (1)
| Title |
|---|
| NAI-YUN JI，ET A1.: "Aspeverin, a new alkaloid from an algicolous strain of Aspergillus versicolor", 《ORGANIC LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103251609A (en) | Application of Aspeverin in preparation of medicines for treating tongue cancer | |
| CN103251605A (en) | Application of Myriberine A in preparing medicine for treating breast cancer | |
| CN103316008A (en) | Application of Aspeverin in preparation of medicine for treating rectal cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN103263431A (en) | Application of polyflavanostilbene A in preparation of medicaments for treating tongue carcinoma | |
| CN103251638A (en) | Application of Polyflavanostilbene A in preparing medicine for treating pancreatic cancer | |
| CN103405407A (en) | Application of compound in preparation of medicines for treating pancreatic cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN103330713A (en) | Application of Aspeverin in preparation of medicine for treating tongue cancer | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine | |
| CN103432111A (en) | Application of compound to preparation of drug for treating rectal cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN103316012A (en) | Application of Aspeverin in preparation of medicine for treating pancreas cancer | |
| CN103316009A (en) | Application of Aspeverin in preparation of medicine for treating cervical carcinoma | |
| CN103316011A (en) | Application of Aspeverin in preparation of medicine for treating skin cancer | |
| CN103251624A (en) | Application of Aspeverin in preparation of medicines for treating ovarian cancer | |
| CN103251617A (en) | Application of Aspeverin in preparation of medicines for treating urinary bladder cancer | |
| CN103263420A (en) | Application of myriberine A in preparation of medicaments for treating tongue carcinoma | |
| CN103251613A (en) | Application of Aspeverin in preparation of medicines for treating ileocecum cancer | |
| CN103316010A (en) | Application of Aspeverin in preparation of medicine for treating liver cancer | |
| CN103251604A (en) | Application of Myriberine A in preparing medicine for treating renal cancer | |
| CN103462974A (en) | Application of Incarviatone A in medicaments for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131002 |